Slide 1: Cover letter to stock exchanges: Q3 FY26 Earnings Presentation
February 12, 2026 Corporate Relationship Department Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd Mumbai 400 001 Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: - Q3 FY 26 Earnings Presentation Please find enclosed herewith the Earnings Prese
Slide 2: NATCO Pharma Limited Earnings Presentation Q3FY26
NATCO Pharma Limited Earnings Presentation Q3FY26
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background information about the
Slide 4: Q3FY26 - Key Business & Consolidated Financial Highlights
Q3FY26 - Key Business & Consolidated Financial Highlights Total Revenue for Q3FY26 stood at INR 705.4 Mn | Pharma Export Formulations at INR 4,214 Mn | Domestic Pharma Formulations Revenue at 1,198 Mn Earnings Before Interest Tax Depreciation and Amortization stood at INR 2,168 Mn and EBITDA Margin
Slide 5: Q3FY26 - Quarterly Performance
Q3FY26 - Quarterly Performance Revenue Breakup (%) – Q3FY26 Revenue Breakup (INR Mn) Q3FY26 Q3FY25 Q2FY26 10.1 9.1 API Revenue 643 666 539 4 Formulation 59.7 17 Formulation – Exports (incl profit share, license income, 4,214 2,858 11,470 export service income & Subsidiaries) Export formulation Domes
Slide 6: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit & Loss Statement (INR Mn) Q3FY26 Q3FY25 Q2FY26 Total Revenue 7,054 6,511 14,630 Total Expenses (before finance cost and depreciation) 4,886 4,360 7,838 Earnings before interest, tax, depreciation and amortization (EBITDA) 2,168 2,151 6,792 EBITDA Margin* (
Slide 7: Key Product Pipeline - USA
Key Product Pipeline - USA Para IVs in the pipeline, with 30 over 20 FTFs (incl. Sole and 14 Approved (either tentative or fully) Shared) Key Solo FTFs (Para IV) in the pipeline Key Para IV products in the pipeline (Filing on NCE-1) date Therapeutic segment/ Therapeutic segment/ Brand Molecule Brand
Slide 8: Our NCE | Cell & Gene Therapy Investments
Our NCE | Cell & Gene Therapy Investments 1 eGenesis 3 Cellogen Therapeutics Invested US$ 8 million in a biotechnology company Invested US$ 2 million focused on advanced cellular focused on xenotransplantation, by developing safe and engineering methods and gene-therapy-based effective human compati
Slide 9: Earnings Call Details – Q3FY26
Earnings Call Details – Q3FY26 The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer and Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences are as below: Details of the Earnings ca